Summary
We expanded the project horizon by collaborating with Naomi Taylor (CCR) and Paul François (UMontréal) in order to usher new Chimetic Antigen Receptor (CAR) T cells. CAR T cell therapy has been transformative for blood cancers but remains limited in treating solid tumors due to on-target/off-tumor (OTOT) toxicity. To address this, we engineered T cells to co-express both a chimeric antigen receptor (CAR) and a neoantigen-specific T cell receptor (TCR), enabling "fuzzy logic" control of T cell activation. Unlike conventional Boolean logic systems, our approach allowed for graded responses shape
